sabato, 17 ottobre 2026

Notizie AIOM – anno XIV n. 599

Moving Programmed Death-1 Inhibitors to the Front Lines in Non–Small-Cell Lung Cancer

Immune checkpoint inhibitors have dramatically reshaped the landscape of non–small-cell lung cancer (NSCLC). In particular, monoclonal antibodies targeting the programmed death-1 (PD-1)/PD ligand 1 (PD-L1) pathway have emerged as powerful new therapeutic tools. In ...
Leggi tutto

30 Settembre 2016

No Conflict, No Interest

Oncology research and clinical advancements often require financial partnerships and collaborations between industry and oncology physicians and researchers. These relationships between oncology and industry are increasing, and concerns exist regarding the extent to which ...
Leggi tutto

30 Settembre 2016

Long-Term Follow-up of Small Pulmonary Ground-Glass Nodules Stable for 3 Years: Implications of the Proper Follow-up Period and Risk Factors for Subsequent Growth

How long persistent and stable ground-glass nodules (GGNs) should be followed is uncertain, although a minimum of 3 years is suggested. Here, we evaluated a group of GGNs that had remained stable for an initial period of 3 years with the aim of determining the proportion ...
Leggi tutto

30 Settembre 2016

Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Nivolumab, a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody, has demonstrated improved survival in previously treated patients with advanced non–small-cell lung cancer (NSCLC). CheckMate 012, a phase I, multicohort study, was ...
Leggi tutto

30 Settembre 2016

26 settembre 2016 – In UK una nuova iniziativa per decisioni condivise tra medici e pazienti

30 Settembre 2016

26 settembre 2016 – Come interpretare i risultati dei trial. Spunti dal NEJM

30 Settembre 2016

27 settembre 2016 – Tabelle farmaci di classe A e H al 15/07/2016

30 Settembre 2016

27 settembre 2016 – Attivazione del Registro Pembrolizumab

30 Settembre 2016

27 settembre 2016 – Attivazione del Registro Nivolumab

30 Settembre 2016

28 settembre 2016 – Pharmacovigilance Joint Action SCOPE: il contributo dell’AIFA nel corso di formazione per assessor di farmacovigilanza